141 search results
Pembrolizumab
KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence.
Pembrolizumab
Treatment of recurrent locally advanced or metastatic oesophageal cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have received prior systemic therapy.
Pembrolizumab
Keytruda, in combinatie metcarboplatine en ofwelpaclitaxel of nab-paclitaxel, is geïndiceerd voor de eerstelijnsbehandeling van gemetastaseerd plaveiselcel-NSCLC bij volwassenen.
Pembrolizumab
2/3L Triple negative metastatic breast cancer
Pembrolizumab
1L bladder carcinoma stage III/IV, including cisplatin-eligible.
Pembrolizumab
Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.
Pembrolizumab
Advanced Hepatocellular Carcinoma in combination with lenvatinib (1L).
Pembrolizumab
Indication for treatment in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.
Pembrolizumab
Treatment in the neoadjuvant or adjuvant setting of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Pembrolizumab / favezelimab
Patients With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer